In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the mRNA platform and how it quickens vaccine production

The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of

This flu season, some people will have a choice between getting the standard flu shot or the new mRNA flu vaccine, according to researchers. The U.S. Food and Drug Administration has approved Moderna's mRNA-1010 flu shot for ages 50 and older.

For older adults, the flu vaccine could look a little different this year.

With the commercialization of mRNA vaccines against COVID-19, research and development into the application of mRNA in vaccines and pharmaceuticals is accelerating. In particular, it is attracting attention not only in vaccines for preventing infectious diseases but also in cancer immunotherapy.

In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines fighting against infectious disease, cancer and autoimmune conditions, faster and more efficiently than the industry standard.

The US Food and Drug Administration on Wednesday approved the United States’ first mRNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.

A Moderna and Merck mRNA vaccine paired with Keytruda reduced melanoma recurrence or death risk by 49% over five years.